<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Sirona Biochem Corp.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:ccb099ac-a38a-4a7b-be95-5e4e6b96d409;id=7777</id> <rights type="text">Copyright 2024, Sirona Biochem Corp.</rights> <updated>2024-11-20T21:30:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/wy9Hqy0LVpwaBD_h-kQZTQ==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/wy9Hqy0LVpwaBD_h-kQZTQ==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/11/20/2984794/0/en/Sirona-Biochem-Announces-Publication-of-Groundbreaking-Study-on-TFC-1326-Compound-in-the-Journal-of-Cosmetic-Dermatology.html</id> <title type="text">Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology</title> <published>2024-11-20T21:30:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/20/2984794/0/en/Sirona-Biochem-Announces-Publication-of-Groundbreaking-Study-on-TFC-1326-Compound-in-the-Journal-of-Cosmetic-Dermatology.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious <em>Journal of Cosmetic Dermatology</em>.</p>]]></content> <dc:identifier>2984794</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 20 Nov 2024 21:30 GMT</dc:modified> <dc:subject>Market Research Reports</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/25/2952986/0/en/SIRONA-BIOCHEM-Poised-for-Profitability-in-2025-with-Anti-Aging-Product-Rollout.html</id> <title type="text">SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout</title> <published>2024-09-25T13:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/25/2952986/0/en/SIRONA-BIOCHEM-Poised-for-Profitability-in-2025-with-Anti-Aging-Product-Rollout.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6t9Xaj0S5jNxdDC8STOsMyWxU0d0lo5vXCQMu-NLkIZhBLZ3gA7IWXbCCE8sbQrTOxPDtDtXVja9WBrylakD_XbbaYSGrV4U80MlPZ8oGSs=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) provides the following update:</p>]]></content> <dc:identifier>2952986</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 25 Sep 2024 13:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/06/18/2900586/0/en/GlycoProteMim-Featured-in-Stonegate-Healthcare-s-Latest-Anti-Aging-Research-Report.html</id> <title type="text">GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report</title> <published>2024-06-18T14:35:20Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/06/18/2900586/0/en/GlycoProteMim-Featured-in-Stonegate-Healthcare-s-Latest-Anti-Aging-Research-Report.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report, "Novel Treatments for Age-Related Skin Problems." The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.<br></p>]]></content> <dc:identifier>2900586</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Tue, 18 Jun 2024 14:36 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Research Analysis and Reports</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/07/2876691/0/en/Sirona-Biochem-Engages-Stonegate-Healthcare-Partners.html</id> <title type="text">Sirona Biochem Engages Stonegate Healthcare Partners</title> <published>2024-05-07T12:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/07/2876691/0/en/Sirona-Biochem-Engages-Stonegate-Healthcare-Partners.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate’s extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona’s anti-aging ingredient, GlycoProteMimTM, to effectively assess and demonstrate its market potential within the global anti-aging skincare industry.<br></p>]]></content> <dc:identifier>2876691</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Tue, 07 May 2024 12:01 GMT</dc:modified> <dc:subject>Partnerships</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/04/08/2858883/0/en/SIRONA-BIOCHEM-Corporate-Update-April-2024.html</id> <title type="text">SIRONA BIOCHEM Corporate Update April 2024</title> <published>2024-04-08T06:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/04/08/2858883/0/en/SIRONA-BIOCHEM-Corporate-Update-April-2024.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=91VGkH6lQznNiD9bf8xUeXMeWEu4FO7kb0aANMy6TYeKUh33zSHMs8pvkfR_F6HwG1VI5TICmeB4XSSs3VpDJYSkznc2_Ac72xIbn3NbL9M=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) provides the following update:<br></p>]]></content> <dc:identifier>2858883</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 08 Apr 2024 06:00 GMT</dc:modified> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/04/05/2858271/0/en/Sirona-Biochem-Announces-Close-of-Private-Placement.html</id> <title type="text">Sirona Biochem Announces Close of Private Placement</title> <published>2024-04-05T01:24:28Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/04/05/2858271/0/en/Sirona-Biochem-Announces-Close-of-Private-Placement.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- <strong>Vancouver, British Columbia</strong> – April 4, 2024 – <a href="https://www.globenewswire.com/Tracker?data=_jHkOQAXOZ2ksPgBIxCFaP-HDPZ9BhrNy2Wved1JgfuxGmvZ2sm_AeEnS13ybkfgd3rz8inzFzk1ok1P_93Ra8hzEN-yio0lKdeoJu62W4U=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (Frankfurt: ZSB) (“<strong>Sirona</strong>”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the “Units”) at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.<br></p>]]></content> <dc:identifier>2858271</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Fri, 05 Apr 2024 01:24 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> <dc:subject>Changes in company's own shares</dc:subject> <dc:subject>Warrants and Certificates</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/28/2854520/0/en/Sirona-Biochem-Announces-2023-Annual-Meeting-Results.html</id> <title type="text">Sirona Biochem Announces 2023 Annual Meeting Results</title> <published>2024-03-28T21:00:12Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/28/2854520/0/en/Sirona-Biochem-Announces-2023-Annual-Meeting-Results.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=agFvFDRwQL2d2JSuZFN07PYaZShOmV-joXsMmsEYfLqfAPP1D61MAfgPwH9lLkzTLmYxrb1Ww2WjfcSCN-SY9mxidIRJNljwYDT03rKwHN4=" rel="nofollow" target="_blank" title="Sirona Biochem Corp.">Sirona Biochem Corp.</a> (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares.<br></p>]]></content> <dc:identifier>2854520</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 28 Mar 2024 21:00 GMT</dc:modified> <dc:subject>Annual Meetings & Shareholder Rights</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/13/2845482/0/en/Sirona-Biochem-Receives-Commercial-Grade-GlycoProteMim-Based-Anti-Aging-Serum-Formulations.html</id> <title type="text">Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations</title> <published>2024-03-13T13:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/13/2845482/0/en/Sirona-Biochem-Receives-Commercial-Grade-GlycoProteMim-Based-Anti-Aging-Serum-Formulations.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pg8Vn2TItFdi0oHiGqFjLdQ91vHlMZmKBwiYYx_o6c1YSdyMzv70JSkcEphbuKugCFnigDqbnMziRQOZqBFtmskLLd512XpgzNedMbxdOfI=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.<br></p>]]></content> <dc:identifier>2845482</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 13 Mar 2024 13:01 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/02/21/2832793/0/en/Sirona-Biochem-Announces-Plans-for-Commercial-Launch-of-GlycoProteMim-in-Early-2025.html</id> <title type="text">Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025</title> <published>2024-02-21T14:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/02/21/2832793/0/en/Sirona-Biochem-Announces-Plans-for-Commercial-Launch-of-GlycoProteMim-in-Early-2025.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to the markets of North America and Europe in early 2025.</p>]]></content> <dc:identifier>2832793</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 21 Feb 2024 14:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/02/15/2830458/0/en/Sirona-Biochem-Provides-Update-on-Loan.html</id> <title type="text">Sirona Biochem Provides Update on Loan</title> <published>2024-02-15T22:50:38Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/02/15/2830458/0/en/Sirona-Biochem-Provides-Update-on-Loan.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=TjOAjKxi1wqqO_TwBur11DRedCS0Fk-6SffJBiroS4Ja_QcOzhGjOsIGaErD2-FWpW-kV7T8a6_rHlvQPrUNXRMGKawtxhZ5Zrv4S5Xt4PE=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the “<strong>Amended Note</strong>”) with 0906462 B.C. Ltd. (the “<strong>Lender</strong>”). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the “<strong>Loan</strong>”). Pursuant to the terms and conditions of the Amended Note:<br></p>]]></content> <dc:identifier>2830458</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 15 Feb 2024 22:51 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/02/15/2830013/0/en/Sirona-Biochem-Engages-Global-Beauty-Consulting.html</id> <title type="text">Sirona Biochem Engages Global Beauty Consulting</title> <published>2024-02-15T14:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/02/15/2830013/0/en/Sirona-Biochem-Engages-Global-Beauty-Consulting.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=GlTNzIEPo1_xKS4p4TVo61gmnjDNhTzdofgirt0j-mC8fzcb1_bki1LcHLLBTtwdu40_aQeJi3CdQ2J7lQKFYkHrXdcCDOO99fsPdYw7KMY=" rel="nofollow" target="_blank" title="Sirona Biochem Corp.">Sirona Biochem Corp.</a> (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMim<sup>TM</sup> in anticipation of its launch in the first quarter of 2025.<br></p>]]></content> <dc:identifier>2830013</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 15 Feb 2024 14:01 GMT</dc:modified> <dc:subject>Business Contracts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/29/2818908/0/en/Sirona-Biochem-Announces-Loan.html</id> <title type="text">Sirona Biochem Announces Loan</title> <published>2024-01-29T13:30:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/29/2818908/0/en/Sirona-Biochem-Announces-Loan.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IlX342yN6PUxbu8O-_gOYYGFwT2R3tHugF_COdjZFtigBzmBWVcqmFXSuMlXwApL9irKBbhGtNhQAMcXMfw4J0UVQ4ughZjO3oeJO7ARVN4=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) announced that it has entered into a demand grid promissory note (the “<strong>Note</strong>”) with 0906462 B.C. Ltd. (the “<strong>Lender</strong>”) for a loan in the aggregate principal amount of up to $1,000,000 (the “<strong>Loan</strong>”). Pursuant to the terms and conditions of the Note:<br></p>]]></content> <dc:identifier>2818908</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 29 Jan 2024 13:30 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> <dc:subject>Corporate Action</dc:subject> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/26/2818319/0/en/Sirona-Biochem-Initiates-Private-Placement.html</id> <title type="text">Sirona Biochem Initiates Private Placement</title> <published>2024-01-26T23:07:40Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/26/2818319/0/en/Sirona-Biochem-Initiates-Private-Placement.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF) (the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 CAD per Unit (a "Unit") for gross proceeds of up to CAD$1,000,000 (the "Private Placement"). Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two.</p>]]></content> <dc:identifier>2818319</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Fri, 26 Jan 2024 23:08 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/24/2815680/0/en/CORRECTION-Sirona-Biochem-Corporate-Update-January-2024.html</id> <title type="text">CORRECTION -- Sirona Biochem Corporate Update January 2024</title> <published>2024-01-24T16:14:08Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/24/2815680/0/en/CORRECTION-Sirona-Biochem-Corporate-Update-January-2024.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1<sup>st</sup> quarter of 2025, not the 1<sup>st</sup> quarter of 2024 as previously stated. The corrected release follows:</p>]]></content> <dc:identifier>2815680</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 24 Jan 2024 16:14 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/24/2814750/0/en/Sirona-Biochem-Corporate-Update-January-2024.html</id> <title type="text">Sirona Biochem Corporate Update January 2024</title> <published>2024-01-24T06:30:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/24/2814750/0/en/Sirona-Biochem-Corporate-Update-January-2024.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update:<br></p>]]></content> <dc:identifier>2814750</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 24 Jan 2024 06:30 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/15/2808928/0/en/Sirona-Biochem-Launches-Cosmetics-Subsidiary-Sirona-Laboratories.html</id> <title type="text">Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™</title> <published>2024-01-15T06:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/15/2808928/0/en/Sirona-Biochem-Launches-Cosmetics-Subsidiary-Sirona-Laboratories.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona Laboratories<sup>TM</sup> - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMim<sup>TM</sup>.<br></p>]]></content> <dc:identifier>2808928</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 15 Jan 2024 06:00 GMT</dc:modified> <dc:subject>Management statements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/12/11/2793989/0/en/Sirona-Biochem-Initiates-GlycoProteMim-Trademark-for-Anti-Aging-Molecule-TFC-1326.html</id> <title type="text">Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326</title> <published>2023-12-11T14:50:09Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/12/11/2793989/0/en/Sirona-Biochem-Initiates-GlycoProteMim-Trademark-for-Anti-Aging-Molecule-TFC-1326.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), is making a strategic move in the world of advanced skincare solutions. Today, the company announces the trademarking of its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™.<br></p>]]></content> <dc:identifier>2793989</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 11 Dec 2023 14:51 GMT</dc:modified> <dc:subject>Patents</dc:subject> <dc:keyword>anti-aging</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/10/25/2767035/0/en/Sirona-Biochem-Announces-Change-of-Auditor.html</id> <title type="text">Sirona Biochem Announces Change of Auditor</title> <published>2023-10-25T22:28:25Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/10/25/2767035/0/en/Sirona-Biochem-Announces-Change-of-Auditor.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the “Company") announces that it has changed its auditors from DeVisser Gray LLP (the “Former Auditor”) Davidson and Company (the “Successor Auditor”) effective October 25, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective October 25, 2023 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor’s audit reports for the relevant period, being the financial years ended October 31, 2021 and October 31, 2022 and any period subsequent to the most recently completed financial year for which an audit report was issued and preceding the resignation of the Former Auditor. In accordance with National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), the Company has filed a Change of Auditor Notice (the “Notice”) on SEDAR together with letters from both the Former Auditor and Successor Auditor, with each lettering confirming agreement with the statements contained in the Notice, as applicable. There were no reportable events as defined in NI 51-102 between the Former Auditor and the Company.<br></p>]]></content> <dc:identifier>2767035</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 25 Oct 2023 22:29 GMT</dc:modified> <dc:subject>Management Changes</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/10/20/2764250/0/en/Sirona-Biochem-Announces-Payment-of-Convertible-Debenture-Interests-in-Shares.html</id> <title type="text">Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares</title> <published>2023-10-20T20:50:01Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/10/20/2764250/0/en/Sirona-Biochem-Announces-Payment-of-Convertible-Debenture-Interests-in-Shares.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center"><strong><em>N</em></strong><strong><em>O</em></strong><strong><em>T</em></strong> <strong><em>F</em></strong><strong><em>O</em></strong><strong><em>R</em></strong> <strong><em>D</em></strong><strong><em>I</em></strong><strong><em>SSE</em></strong><strong><em>M</em></strong><strong><em>I</em></strong><strong><em>N</em></strong><strong><em>A</em></strong><strong><em>T</em></strong><strong><em>I</em></strong><strong><em>O</em></strong><strong><em>N</em></strong> <strong><em>I</em></strong><strong><em>N </em></strong><strong><em>T</em></strong><strong><em>H</em></strong><strong><em>E</em></strong> <strong><em>U</em></strong><strong><em>S</em></strong> <strong><em>O</em></strong><strong><em>R</em></strong> <strong><em>T</em></strong><strong><em>H</em></strong><strong><em>R</em></strong><strong><em>O</em></strong><strong><em>U</em></strong><strong><em>G</em></strong><strong><em>H </em></strong><strong><em>U</em></strong><strong><em>S</em></strong> <strong><em>N</em></strong><strong><em>E</em></strong><strong><em>W</em></strong><strong><em>SW</em></strong><strong><em>I</em></strong><strong><em>RE</em></strong> <strong><em>SER</em></strong><strong><em>V</em></strong><strong><em>IC</em></strong><strong><em>E</em></strong><strong><em>S</em></strong><br></p>]]></content> <dc:identifier>2764250</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Fri, 20 Oct 2023 20:50 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/07/13/2704404/0/en/Sirona-Biochem-Corporate-Update.html</id> <title type="text">Sirona Biochem Corporate Update</title> <published>2023-07-13T13:00:00Z</published> <updated>2024-11-24T15:14:33Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/07/13/2704404/0/en/Sirona-Biochem-Corporate-Update.html" /> <category term="TSX-V:SBM" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Other OTC:SRBCF" scheme="https://www.globenewswire.com/rss/stock" /> <category term="Frankfurt:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="XETRA:ZSB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA82967M1005" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">VANCOUVER, British Columbia, July 13, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=veZ5dvZiNoINjJnoReIc2wTfxVULlNItxz9483G6MeTvhpYPZ1TM16XgITf2sirCFC0P9iXRln5sfXzcyDxnVCfi5kwCJ5XRI36pMiPIpc0=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>”) provides the following update:<br></p>]]></content> <dc:identifier>2704404</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 13 Jul 2023 13:02 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Stock Market News</dc:subject> <dc:keyword>biotech</dc:keyword> <dc:keyword>vancouver biotech</dc:keyword> <dc:keyword>anti-aging</dc:keyword> <dc:keyword>dermatology</dc:keyword> <dc:keyword>antiviral</dc:keyword> <dc:keyword>pharmaceutical</dc:keyword> <dc:keyword>skincare</dc:keyword> </entry> </feed>